AstraZeneca secures US FDA approval for Brilinta for long term use
The regulatory authority has approved Brilinta tablets at a new dose that could be taken along with aspirin beyond a year of heart attack, reported Reuters. In July
Boehringer Ingelheim India has signed a memorandum of understanding (MoU) to enhance pharmaceutical education and research collaboration.
The approval is based on four trials of patients receiving emetogenic chemotherapy, including cisplatin, carboplatin and anthracycline/cyclophosphamide-based regimens. Varubi is a selective and competitive antagonist of human substance
It enables preclinical development of Ocata’s proprietary photoreceptor progenitor product for the treatment of retinal degenerative diseases, such as retinitis pigmentosa (RP) and photoreceptor dystrophies. Ocata chief scientific